{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-005714","form_type":"8-K","ticker":"DYN","cik":"0001818794","company_name":"Dyne Therapeutics, Inc.","filed_at":"2023-03-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.748767+00:00","generated_at":"2026-06-18T15:49:14.901088+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Dyne Therapeutics reports FY2022 net loss $168.1M; cash $256M; data readouts H2 2023","bullets":["Cash, cash equivalents and marketable securities $256.0M as of Dec 31, 2022; expected to fund operations through 2024.","Net loss Q4 2022 $38.8M ($0.74/share) vs $51.8M ($1.00/share) in Q4 2021; full year net loss $168.1M ($3.23/share).","R&D expenses FY2022 $142.8M, up from $121.3M in FY2021; G&A expenses $28.2M vs $28.7M.","Enrollment continues in ACHIEVE (DYNE-101 in DM1) and DELIVER (DYNE-251 in DMD) Phase 1/2 registrational trials.","Initial data from MAD placebo-controlled portions of both trials anticipated in second half of 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-005714","json":"https://secwatch.observer/filing/0000950170-23-005714.json","markdown":"https://secwatch.observer/filing/0000950170-23-005714.md","text":"https://secwatch.observer/filing/0000950170-23-005714.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1818794/000095017023005714/0000950170-23-005714-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1818794/000095017023005714/dyn-20230302.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T15:49:14.901088+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"481393245beb9526e632b8fcff5b3804e4b01c4c","claim":"Dyne Therapeutics, Inc. reported the quarter ended December 31, 2022 results: net income Net loss for the quarter ended December 31, 2022 was $38.8 million, or $0.74 per basic and diluted share., EPS $0.74 per basic and diluted share.","evidence_excerpt":"Net loss for the quarter ended December 31, 2022 was $38.8 million, or $0.74 per basic and diluted share.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017023005714/0000950170-23-005714-index.htm","confidence":0.99,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended December 31, 2022"},{"label":"Net income","value":"Net loss for the quarter ended December 31, 2022 was $38.8 million, or $0.74 per basic and diluted share."},{"label":"EPS","value":"$0.74 per basic and diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"b7403f84b678ff018db24965dab653c82c6729a1","claim":"Dyne Therapeutics, Inc. reported the year ended December 31, 2022 results: net income Net loss for the year ended December 31, 2022 was $168.1 million, or $3.23 per basic and diluted share., EPS $3.23 per basic and diluted share.","evidence_excerpt":"Net loss for the year ended December 31, 2022 was $168.1 million, or $3.23 per basic and diluted share.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017023005714/0000950170-23-005714-index.htm","confidence":0.99,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2022"},{"label":"Net income","value":"Net loss for the year ended December 31, 2022 was $168.1 million, or $3.23 per basic and diluted share."},{"label":"EPS","value":"$3.23 per basic and diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}